Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, United States of America.
PLoS One. 2021 Aug 19;16(8):e0254125. doi: 10.1371/journal.pone.0254125. eCollection 2021.
Imaging techniques based on fluorescence and bioluminescence have been important tools in visualizing tumor progression and studying the effect of drugs and immunotherapies on tumor immune microenvironment in animal models of cancer. However, transgenic expression of foreign proteins may induce immune responses in immunocompetent syngeneic tumor transplant models and augment the efficacy of experimental drugs. In this study, we show that the growth rate of Lewis lung carcinoma (LL/2) tumors was reduced after transduction of tdTomato and luciferase (tdTomato/Luc) compared to the parental cell line. tdTomato/Luc expression by LL/2 cells altered the tumor microenvironment by increasing tumor-infiltrating lymphocytes (TILs) while inhibiting tumor-induced myeloid-derived suppressor cells (MDSCs). Interestingly, tdTomato/Luc expression did not alter the response of LL/2 tumors to anti-PD-1 and anti-CTLA-4 antibodies. These results suggest that the use of tdTomato/Luc-transduced cancer cells to conduct studies in immune competent mice may lead to cell-extrinsic tdTomato/Luc-induced alterations in tumor growth and tumor immune microenvironment that need to be taken into consideration when evaluating the efficacy of anti-cancer drugs and vaccines in immunocompetent animal models.
基于荧光和生物发光的成像技术已成为在癌症动物模型中可视化肿瘤进展和研究药物及免疫疗法对肿瘤免疫微环境影响的重要工具。然而,在免疫活性同基因肿瘤移植模型中转基因表达外源蛋白可能会引起免疫反应,并增强实验药物的疗效。在这项研究中,我们发现与亲本细胞系相比,转导 tdTomato 和荧光素酶(tdTomato/Luc)后 Lewis 肺癌(LL/2)肿瘤的生长速度降低。LL/2 细胞的 tdTomato/Luc 表达通过增加肿瘤浸润淋巴细胞(TILs)而抑制肿瘤诱导的髓系来源抑制细胞(MDSCs),从而改变肿瘤微环境。有趣的是,tdTomato/Luc 的表达并未改变 LL/2 肿瘤对抗 PD-1 和抗 CTLA-4 抗体的反应。这些结果表明,使用转导 tdTomato/Luc 的癌细胞在免疫活性小鼠中进行研究可能导致细胞外在的 tdTomato/Luc 诱导的肿瘤生长和肿瘤免疫微环境改变,在评估免疫活性动物模型中抗癌药物和疫苗的疗效时需要考虑这些改变。
Methods Mol Biol. 2024
Mol Ther. 2023-8-2
Cancers (Basel). 2022-12-25
Cancer Immunol Res. 2022-11-2
Cancers (Basel). 2022-8-30
Tissue Eng Part C Methods. 2018-4-10
Curr Pharm Biotechnol. 2017
Vaccines (Basel). 2016-11-3
Stem Cell Rev Rep. 2016-10